Attached files

file filename
XML - IDEA: XBRL DOCUMENT - CytoCore IncR22.htm
EXCEL - IDEA: XBRL DOCUMENT - CytoCore IncFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - CytoCore IncR8.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR6.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR9.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR2.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR31.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR33.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR35.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR28.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR32.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR37.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR30.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR29.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR25.htm
EX-32.1 - EXHIBIT 32.1 - CytoCore Incv326519_ex32-1.htm
EX-31.1 - EXHIBIT 31.1 - CytoCore Incv326519_ex31-1.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR5.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR1.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR4.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR3.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR7.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR24.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR19.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR27.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR21.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR36.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR12.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR13.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR14.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR16.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR17.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR10.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR34.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR18.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR38.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR23.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR15.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR26.htm
10-Q - FORM 10-Q - CytoCore Incv326519_10q.htm
XML - IDEA: XBRL DOCUMENT - CytoCore IncR11.htm
v2.4.0.6
Stockholders' Equity (Deficit) (Tables)
9 Months Ended
Sep. 30, 2012
Stockholders' Equity (Deficit) [Abstract]  
Reconciliation of Numerator and Denominator Used in Calculation of Loss Per Share

A reconciliation of the numerator and the denominator used in the calculation of loss per share is as follows:

           

    Nine months ended     Three months ended  
    September 30,
 2012
    September 30,
2011
    September 30,
2012
    September 30,
2011
 
    (unaudited)     (unaudited)  
             
Basic and Diluted:                                
Net loss applicable to common stockholder   $ (1,208 )   $ (1,749 )   $ (53 )   $ (627 )
Weighted average common shares outstanding     70,278,553       55,644,245       72,964,624       59,759,909  
Net loss per common share   $ (0.02 )   $ (0.03 )   $ (0.00 )   $ (0.01 )
Summary of Company's Preferred Stock

A summary of the Company’s preferred stock is as follows:

 

  September 30,  December 31, 
  2012  2011 
  Shares Issued &  Shares Issued & 
Offering  Outstanding   Outstanding 
  (unaudited)     
         
Series A convertible  47,250   47,250 
Series B convertible, 10% cumulative dividend  93,750   93,750 
Series C convertible, 10% cumulative dividend  38,333   38,333 
Series D convertible, 10% cumulative dividend  175,000   175,000 
Series E convertible, 10% cumulative dividend  19,022   19,022 
Total Preferred Stock  373,355   373,355 

 

Summary of Preferred Stock Terms

Summary of Preferred Stock Terms

 

Series A Convertible Preferred Stock

Liquidation Value:$4.50 per share, $212,625
Conversion Price:$103.034 per share
Conversion Rate:0.04367—Liquidation Value divided by Conversion Price ($4.50/$103.034)
Voting Rights:None
Dividends:None
Conversion Period:Any time

 

Series B Convertible Preferred Stock

Liquidation Value:$4.00 per share, $375,000
Conversion Price:$10.00 per share
Conversion Rate:0.40—Liquidation Value divided by Conversion Price ($4.00/$10.00)
Voting Rights:None
Dividends:10%—Quarterly—Commencing March 31, 2001
Conversion Period:Any time
Cumulative and undeclared dividends in arrears at September 30, 2012 were $435,000

 

Series C Convertible Preferred Stock
Liquidation Value:$3.00 per share, $115,000
Conversion Price:$6.00 per share
Conversion Rate:0.50—Liquidation Value divided by Conversion Price ($3.00/$6.00)
Voting Rights:None
Dividends:10%—Quarterly—Commencing March 31, 2002
Conversion Period:Any time

Cumulative and undeclared dividends in arrears at June 30, 2012 were $126,000

 

Series D Convertible Preferred Stock

Liquidation Value:$10.00 per share, $1,750,000
Conversion Price:$10.00 per share
Conversion Rate:1.00—Liquidation Value divided by Conversion Price ($10.00/$10.00)
Voting Rights:None
Dividends:10%—Quarterly—Commencing April 30, 2002
Conversion Period:

Any time

Cumulative and undeclared dividends in arrears at June 30, 2012 were $1,911,000

 

Series E Convertible Preferred Stock

Liquidation Value:$22.00 per share, $418,488
Conversion Price:$8.00 per share
Conversion Rate:2.75—Liquidation Value divided by Conversion Price ($22.00/$8.00)
Voting Rights:Equal in all respects to holders of common shares
Dividends:10%—Quarterly—Commencing May 31, 2002
Conversion Period:

Any time

Cumulative and undeclared dividends in arrears at June 30, 2012 were $460,000.